Novel fabrication of hydroxypropyl-β-cyclodextrin functionalized zein protein nanoparticles Co-encapsulated with bio-molecules to attenuate pregnancy-induced hypertension by inducing trophoblast cells proliferation with TLR4 signaling pathway.
Wang Yalin, Tong Xinyun, He Yin, Huang Ke, Luo Quanhui, Wang Jinxing, Wu Song
{"title":"Novel fabrication of hydroxypropyl-β-cyclodextrin functionalized zein protein nanoparticles Co-encapsulated with bio-molecules to attenuate pregnancy-induced hypertension by inducing trophoblast cells proliferation with TLR4 signaling pathway.","authors":"Wang Yalin, Tong Xinyun, He Yin, Huang Ke, Luo Quanhui, Wang Jinxing, Wu Song","doi":"10.1177/08853282251322272","DOIUrl":null,"url":null,"abstract":"<p><p>Trophoblast dysfunction during pregnancy time is majorly involved to lead pathogenesis of preeclampsia. In the present investigation, the facile nanoformulation by Zein protein particles functionalized with hydroxypropyl-beta-cyclodextrin (β-CD) and co-encapsulated with curcumin and eugenol compounds (Cu/Eu@H-β-CD-ZNPs) is developed to achieve enhanced therapeutic potential in the treatment of preeclampsia. To investigate the positive trophoblast function, trophoblast cells were treated and observed for in vitro cell proliferation, invasion and migration ability under hypoxic condition. The Cu/Eu@H-β-CD-ZNPs have significantly induced the restoration ability of trophoblast cells. In vivo animal study was performed using pregnancy rat models by inducing LPS and observed the hypertension-related factors. The Cu/Eu@H-β-CD-ZNPs prominently down-regulated the expressions of serum and placental pro-inflammatory factors (IL-6, TNF-α, IL1β, and IFN-γ). Additionally, p65 and TLR4 protein expressions in LPS-induced model were effectively downregulated after administration of Cu/Eu@H-β-CD-ZNPs. Results of current investigation provides evidence for combination of Cur/Eug with novel H-β-CD-ZNPs formulation have therapeutic potential on the treatment of pregnancy-induced hypertension by rat models.</p>","PeriodicalId":15138,"journal":{"name":"Journal of Biomaterials Applications","volume":" ","pages":"118-134"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomaterials Applications","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/08853282251322272","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Trophoblast dysfunction during pregnancy time is majorly involved to lead pathogenesis of preeclampsia. In the present investigation, the facile nanoformulation by Zein protein particles functionalized with hydroxypropyl-beta-cyclodextrin (β-CD) and co-encapsulated with curcumin and eugenol compounds (Cu/Eu@H-β-CD-ZNPs) is developed to achieve enhanced therapeutic potential in the treatment of preeclampsia. To investigate the positive trophoblast function, trophoblast cells were treated and observed for in vitro cell proliferation, invasion and migration ability under hypoxic condition. The Cu/Eu@H-β-CD-ZNPs have significantly induced the restoration ability of trophoblast cells. In vivo animal study was performed using pregnancy rat models by inducing LPS and observed the hypertension-related factors. The Cu/Eu@H-β-CD-ZNPs prominently down-regulated the expressions of serum and placental pro-inflammatory factors (IL-6, TNF-α, IL1β, and IFN-γ). Additionally, p65 and TLR4 protein expressions in LPS-induced model were effectively downregulated after administration of Cu/Eu@H-β-CD-ZNPs. Results of current investigation provides evidence for combination of Cur/Eug with novel H-β-CD-ZNPs formulation have therapeutic potential on the treatment of pregnancy-induced hypertension by rat models.
期刊介绍:
The Journal of Biomaterials Applications is a fully peer reviewed international journal that publishes original research and review articles that emphasize the development, manufacture and clinical applications of biomaterials.
Peer-reviewed articles by biomedical specialists from around the world cover:
New developments in biomaterials, R&D, properties and performance, evaluation and applications
Applications in biomedical materials and devices - from sutures and wound dressings to biosensors and cardiovascular devices
Current findings in biological compatibility/incompatibility of biomaterials
The Journal of Biomaterials Applications publishes original articles that emphasize the development, manufacture and clinical applications of biomaterials. Biomaterials continue to be one of the most rapidly growing areas of research in plastics today and certainly one of the biggest technical challenges, since biomaterial performance is dependent on polymer compatibility with the aggressive biological environment. The Journal cuts across disciplines and focuses on medical research and topics that present the broadest view of practical applications of biomaterials in actual clinical use.
The Journal of Biomaterial Applications is devoted to new and emerging biomaterials technologies, particularly focusing on the many applications which are under development at industrial biomedical and polymer research facilities, as well as the ongoing activities in academic, medical and applied clinical uses of devices.